Volume 200, Issue 1, Pages 70.e1-70.e5 (January 2009)
22 of 47
ABSTRACT
SUMMARY PDF (196 KB)
FULL TEXT
FULL-TEXT PDF (244 KB)
GET FULL TEXT ELSEWHERE
CITATION ALERT
CITED BY
RELATED ARTICLES
EXPORT CITATION
EMAIL TO A COLLEAGUE
RIGHTS/PERMISSIONS
DOWNLOAD IMAGES
NEED REPRINTS?
BOOKMARK ARTICLE
High-dose methadone in pregnant women and its effect on duration of neonatal abstinence syndrome
This research was presented at the 28th Annual Meeting of the Society for Maternal–Fetal Medicine, Dallas, TX, Jan. 28-Feb. 2, 2008.
Susie Lim, MDd, Mona R. Prasad, DO, MPHa, Philip Samuels, MDa, Debra K. Gardner, PharmDb, Leandro Cordero, MDc
Received 29 February 2008; received in revised form 1 August 2008; accepted 21 August 2008. published online 03 November 2008.
Objective
The purpose of this study was to examine high-dose methadone in pregnant women and its effect on the duration of neonatal abstinence syndrome.
Study Design
This was a retrospective chart review of 68 neonates and their mothers who received methadone therapy during pregnancy. The last dosage of maternal methadone just before delivery and the length of treatment for neonatal abstinence syndrome were examined with an analysis of variance model.
Results
When the data were analyzed for methadone dosages as a continuous variable, each 1-mg increase in the last maternal methadone dosage before delivery was associated with an additional 0.18 days of infant treatment for neonatal abstinence syndrome (P < .001; 95% CI, 0.112-0.255). In other words, every increase of 5.5 mg of methadone in the mother was associated statistically with 1 additional day of neonatal abstinence syndrome treatment for the infant. Gestational age at delivery and birthweight were not statistically significant.
Conclusion
Higher doses of maternal methadone were associated with an increase in diagnosis and longer duration of neonatal abstinence syndrome.
http://www.ajog.org/article/S0002-9378(08)00977-0/abstract
No comments:
Post a Comment